Toxicity of a second autologous peripheral blood stem cell transplant in patients with relapsed or recurrent multiple myeloma

Leukemia and Lymphoma

Volumn 50, Issue 9, 2009, Pages 1442-1447

  Burzynski, Julianna Aleathea ^a,b   Toro, Juan J ^c   Patel, Rakhi Chhaganbhai ^a,b   Lee, Shuko ^a   Greene, Rebecca Elizabeth ^a,b   Ochoa Bayona, Jose Leonel ^a,c   Frei, Christopher Raymond ^b   Freytes, Cesar O ^a,c  

^a SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^b UNIVERSITY OF TEXAS AT AUSTIN   (United States)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

autologous; hematopoietic stem cell transplantation salvage therapy; Multiple myeloma; toxicity

Indexed keywords

AUTOANTIBODY; AZATHIOPRINE; CHLORAMBUCIL; CORTICOSTEROID; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; FLUDARABINE; GANGLIOSIDE; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; M PROTEIN; MYELIN ASSOCIATED GLYCOPROTEIN; PARAPROTEIN; RITUXIMAB; SULFOGLUCURONYL PARAGLOBOSIDE; UNCLASSIFIED DRUG; VASCULOTROPIN;

AMYLOIDOSIS; ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; BONE MARROW BIOPSY; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL FEATURE; CRYOGLOBULINEMIA; DIAGNOSTIC PROCEDURE; ELECTRODIAGNOSIS; GENOMIC INSTABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NEUROPATHY; OCCUPATIONAL THERAPY; PARAPROTEINEMIC NEUROPATHY; PATHOPHYSIOLOGY; PHYSIOTHERAPY; PLASMAPHERESIS; POEMS SYNDROME; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; ADULT; AGED; AUTOTRANSPLANTATION; DISEASE COURSE; EVALUATION; FEMALE; MALE; MIDDLE AGED; MORTALITY; PATHOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENT DISEASE; REGISTER; RETROSPECTIVE STUDY; SURVIVAL; TREATMENT OUTCOME;

ADULT; AGED; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIPLE MYELOMA; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RECURRENCE; REGISTRIES; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 79952277849     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190903085936     Document Type: Article

References (27)

1. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996;335:91-97. (Pubitemid 26240110)
2. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003;348:1875-1883. (Pubitemid 36532313)
3. Abdelkefi A, Ladeb S, Torjman L, et al. Single autologous stem-cell transplantation followed by maintenance therapy with thalidomide is superior to double autologous transplantation in multiple myeloma: results of a multicenter randomized clinical trial. 2008;111:1805-1810.
4. Alvares CL, Davies FE, Horton C, et al. The role of second autografts in the management of myeloma at first relapse. Haematologica 2006;91:141-142. (Pubitemid 43235400)
5. Cavo M, Tosi P, Zamagni E, et al. Prospective, randomized study of single compared with double autologous stem-cell transplantation for multiple myeloma: Bologna 96 clinical study. J Clin Oncol 2007;25:2434-2441. (Pubitemid 46999214)
6. Fermand JP, Ravaud P, Chevret S, et al. High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized clinical trial. Blood 1998;92:3131-3136. (Pubitemid 28492319)
7. Lee CK, Barlogie B, Zangari M, et al. Transplantation as salvage therapy for high-risk patients with myeloma in relapse. Bone Marrow Transplant 2002;30:873-878. (Pubitemid 36097475)
8. Mehta J, Singhal S. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in myeloma patients under the age of 65 years. Bone Marrow Transplant 2007;40:1101-1114. (Pubitemid 350193802)
9. Mehta J, Tricot G, Jagannath S, et al. Salvage autologous or allogeneic transplantation for multiple myeloma refractory to or relapsing after a first-line autograft? Bone Marrow Transplant 1998;21:887-892. (Pubitemid 28200854)
10. Mehta J, Tricot G, Jagannath S, et al. High-dose chemotherapy with carboplatin, cyclophosphamide and etoposide and autologous transplantation for multiple myeloma relapsing after a previous transplant. Bone Marrow Transplant 1997;20:113-116. (Pubitemid 27356725)
11. Mikhael JR, Zadeh S, Samiee S, et al. Second autologous stem cell transplant (ASCT) as salvage therapy in patients with relapsed multiple myeloma: improved outcomes in patients with longer disease free interval after first ASCT. ASH Annu Meet Abstr 2007;110:946.
12. Morris C, Iacobelli S, Brand R, et al. Benefit and timing of second transplantations in multiple myeloma: clinical findings and methodological limitations in a European Group for Blood and Marrow Transplantation registry study. J Clin Oncol 2004;22:1674-1681. (Pubitemid 41079806)
13. Olin RL, Vogl DT, Porter DL, et al. Second auto-SCT is safe and effective salvage therapy for relapsed multiple myeloma. Bone Marrow Transplant 2009;43:417-422.
14. Qazilbash MH, Saliba R, De Lima M, et al. Second autologous or allogeneic transplantation after the failure of first autograft in patients with multiple myeloma. Cancer 2006;106:1084-1089.
15. Simpson L, Verma R, Kumar S, et al. Outcome after second stem cell transplantation for relapsed multiple myeloma. J Clin Oncol (Meeting Abstracts) 2007;25:8118.
16. Sirohi B, Powles R, Rudin C, et al. Re-use of the original infusional induction chemotherapy as salvage therapy in myeloma patients relapsing after one autograft. Hematology 2005;10:361-364. (Pubitemid 41806522)
17. Tricot G, Jagannath S, Vesole DH, et al. Relapse of multiple myeloma after autologous transplantation: survival after salvage therapy. Bone Marrow Transplant 1995;16:7-11.
18. Cancer Therapy Evaluation Program, Common terminology criteria for adverse events, version 3.0. http://ctepcancergov. 2003.
19. Blade J, Samson D, Reece D, et al. Criteria for evaluating disease response and progression in patients with multiple myeloma treated by high-dose therapy and haemopoietic stem cell transplantation. Myeloma Subcommittee of the EBMT. European Group for Blood and Marrow Transplant. Br J Haematol 1998;102:1115-1123. (Pubitemid 28435189)
20. Barlogie B, Desikan R, Eddlemon P, et al. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients. Blood 2001;98:492-494.
21. Dimopoulos M, Spencer A, Attal M, et al. Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma. N Engl J Med 2007;357:2123-2132. (Pubitemid 350146107)
22. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005;352:2487-2498. (Pubitemid 41007864)
23. Kumar S, Gertz MA, Dispenzieri A, et al. Response rate, durability of response, and survival after thalidomide therapy for relapsed multiple myeloma. Mayo Clin Proc 2003;78:34-39. (Pubitemid 36033958)
24. Mileshkin L, Biagi JJ, Mitchell P, et al. Multicenter phase 2 trial of thalidomide in relapsed/refractory multiple myeloma: adverse prognostic impact of advanced age. Blood 2003;102:69-77. (Pubitemid 36759637)
25. Richardson PG, Sonneveld P, Schuster M, et al. Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial. Blood 2007;110:3557-3560. (Pubitemid 350159621)
26. Weber DM, Chen C, Niesvizky R, et al. Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America. N Engl J Med 2007;357:2133-2142. (Pubitemid 350146108)
27. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide-and lenalidomide-associated thrombosis in myeloma. Leukemia 2008;22:414-423. (Pubitemid 351255436)